Ibrutinib

Coffee consumption may lower the risk for disease progression and death in patients with advanced or metastatic colorectal cancer, according to recently published study results. It was the top story in hematology/oncology last week.

Ibrutinib — a Bruton tyrosine kinase inhibitor that inhibits B cell-receptor signaling — has demonstrated long-term efficacy as treatment for many mature B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.

Since the COVID-19 pandemic began, researchers around the world have joined the effort to develop a vaccine and test potential treatments.

Dana-Farber Cancer Institute announced the launch of a randomized clinical trial evaluating the use of ibrutinib — an oral medication used to treat blood cancer — in patients with COVID-19.

The FDA approved ibrutinib in combination with rituximab for treatment of newly diagnosed patients chronic lymphocytic leukemia or small lymphocytic lymphoma.

Loncastuximab tesirine appeared effective and safe for patients with relapsed or refractory diffuse large B-cell lymphoma, according to topline data released by the agent’s manufacturer.

ORLANDO — In this video at ASH Annual Meeting and Exposition, Ryan W. Jacobs, MD, discusses the implications of the ELEVATE-TN trial, which showed acalabrutinib alone or in combination with obinutuzumab extended PFS compared with obinutuzumab and chlorambucil among patients with treatment-naive chronic lymphocytic leukemia.

ORLANDO — The addition of venetoclax to ibrutinib as a consolidation therapy appeared associated with high rates of undetectable minimal residual disease in bone marrow and complete response within 12 months among patients with high-risk chronic lymphocytic leukemia, according to phase 2 study results presented at ASH Annual Meeting and Exposition.

ORLANDO — Although ibrutinib has been increasingly used for the first-line treatment of chronic lymphocytic leukemia in the community setting, early discontinuation of the agent appeared more prevalent in real-world practice than on clinical trials, according to results of a retrospective cohort study presented at ASH Annual Meeting and Exposition.

ORLANDO – Combining all novel drugs – rituximab, lenalidomide and ibrutinib – to treat diffuse large B-cell lymphoma proved more effective than standard chemotherapy and combinations thereof, according to a poster presenter at the ASH Annual Meeting and Exposition.